Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 陈德章教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1016/S0140-6736(15)00055-0 |
引用次数
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/58Scopus source URL
其它资讯
摘要Epidemiological trends during the past decade suggest that although incidence of nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from the disease has fallen substantially. This finding is probably a result of a combination of lifestyle modification, population screening coupled with better imaging, advances in radiotherapy, and effective systemic agents. In particular, intensity-modulated radiotherapy has driven the improvement in tumour control and reduction in toxic effects in survivors. Clinical use of Epstein-Barr virus (EBV) as a surrogate biomarker in nasopharyngeal carcinoma continues to increase, with quantitative assessment of circulating EBV DNA used for population screening, prognostication, and disease surveillance. Randomised trials are investigating the role of EBV DNA in stratification of patients for treatment intensification and deintensification. Among the exciting developments in nasopharyngeal carcinoma, vascular endothelial growth factor inhibition and novel immunotherapies targeted at immune checkpoint and EBV-specific tumour antigens offer promising alternatives to patients with metastatic disease.
着者Chua ML, Wee JT, Hui EP, Chan AT
期刊名称Lancet
出版年份2016
月份3
日期5
卷号387
期次10022
出版社Elsevier
页次1012 - 1024
国际标準期刊号0140-6736
电子国际标準期刊号1474-547X
语言英式英语
关键词Nasopharyngeal carcinoma
